Literature DB >> 8285636

Bactericidal activity of the fluoroquinolone WIN 57273 against high-level gentamicin-resistant Enterococcus faecalis.

G A Noskin1, P Mehl, J R Warren.   

Abstract

The fluoroquinolone WIN 57273 showed identical bactericidal activities (MBC for 90% of the strains = 0.25 micrograms/ml) for bacteremic strains of Enterococcus faecalis with and without high-level gentamicin resistance. WIN 57273 was bactericidal in time-kill measurements with highly gentamicin-resistant, ciprofloxacin-susceptible strains of E. faecalis. However, WIN 57273 was indifferent with penicillin for gentamicin-resistant E. faecalis and was not bactericidal for ciprofloxacin-resistant E. faecalis.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8285636      PMCID： PMC192411          DOI： 10.1128/AAC.37.11.2470

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  15 in total

1.  Multicenter evaluation of the in vitro activities of three new quinolones, sparfloxacin, CI-960, and PD 131,628, compared with the activity of ciprofloxacin against 5,252 clinical bacterial isolates.

Authors:  P C Fuchs; A L Barry; M A Pfaller; S D Allen; E H Gerlach
Journal:  Antimicrob Agents Chemother       Date:  1991-04       Impact factor: 5.191

2.  In vitro and in vivo activities of a new quinolone, WIN 57273, possessing potent activity against gram-positive bacteria.

Authors:  D M Sedlock; R A Dobson; D M Deuel; G Y Lesher; J B Rake
Journal:  Antimicrob Agents Chemother       Date:  1990-04       Impact factor: 5.191

3.  WIN 57273, a new fluoroquinolone with enhanced in vitro activity versus gram-positive pathogens.

Authors:  G W Kaatz; S M Seo
Journal:  Antimicrob Agents Chemother       Date:  1990-07       Impact factor: 5.191

4.  Endocarditis due to streptomycin-susceptible Enterococcus faecalis with high-level gentamicin resistance.

Authors:  C A Spiegel; M Huycke
Journal:  Arch Intern Med       Date:  1989-08

5.  Comparative in vitro activities of a new quinolone, OPC-17116, possessing potent activity against gram-positive bacteria.

Authors:  H Wakebe; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1992-10       Impact factor: 5.191

6.  High-level gentamicin resistance in Enterococcus faecalis bacteremia.

Authors:  G A Noskin; M Till; B K Patterson; J T Clarke; J R Warren
Journal:  J Infect Dis       Date:  1991-12       Impact factor: 5.226

7.  Antimicrobial activity of DU-6859, a new potent fluoroquinolone, against clinical isolates.

Authors:  K Sato; K Hoshino; M Tanaka; I Hayakawa; Y Osada
Journal:  Antimicrob Agents Chemother       Date:  1992-07       Impact factor: 5.191

8.  Comparative in vitro activity of PD 127391, a new fluoroquinolone agent, against susceptible and resistant clinical isolates of gram-positive cocci.

Authors:  A G Miranda; A R Wanger; K V Singh; B E Murray
Journal:  Antimicrob Agents Chemother       Date:  1992-06       Impact factor: 5.191

9.  In vitro evaluation of WIN 57273, a new broad-spectrum fluoroquinolone.

Authors:  R N Jones; A L Barry
Journal:  Antimicrob Agents Chemother       Date:  1990-02       Impact factor: 5.191

10.  High-content aminoglycoside disks for determining aminoglycoside-penicillin synergy against Enterococcus faecalis.

Authors:  D F Sahm; C Torres
Journal:  J Clin Microbiol       Date:  1988-02       Impact factor: 5.948
View more
  4 in total

Review 1.  Current perspectives on glycopeptide resistance.

Authors:  N Woodford; A P Johnson; D Morrison; D C Speller
Journal:  Clin Microbiol Rev       Date:  1995-10       Impact factor: 26.132

2.  Comparative study of bacteremias caused by Enterococcus spp. with and without high-level resistance to gentamicin. The Grupo Andaluz para el estudio de las Enfermedades Infecciosas.

Authors:  F J Caballero-Granado; J M Cisneros; R Luque; M Torres-Tortosa; F Gamboa; F Díez; J L Villanueva; R Pérez-Cano; J Pasquau; D Merino; A Menchero; D Mora; M A López-Ruz; A Vergara
Journal:  J Clin Microbiol       Date:  1998-02       Impact factor: 5.948

3.  Improved efficacy with nonsimultaneous administration of first doses of gentamicin and ceftazidime in vitro.

Authors:  M L Barclay; E J Begg; S T Chambers; D R Boswell
Journal:  Antimicrob Agents Chemother       Date:  1995-01       Impact factor: 5.191

Review 4.  In vitro activity of fluoroquinolones against gram-positive bacteria.

Authors:  G M Eliopoulos
Journal:  Drugs       Date:  1995       Impact factor: 9.546
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.